RIGEL PHARMACEUTICALS INC (RIGL)
US7665596034 - Common Stock
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the...
Monday Sector Laggards: Biotechnology, Water Utilities
Commit To Buy Rigel Pharmaceuticals At $1, Earn 20.1% Annualized Using Options
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical...
RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023
RIGL stock results show that Rigel Pharmaceuticals beat on revenue for the fourth quarter of 2023.
RIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rigel Pharmaceuticals (NASDAQ:RIGL) just reported results for the fourth quarte...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023,...
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after...
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights...
Rigel Pharmaceuticals Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter of 2023,...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric...
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company...
Commit To Buy Rigel Pharmaceuticals At $1, Earn 32% Annualized Using Options
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year...
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2023, including sales of...
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of four posters highlighting data from their commercial...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close on...
Rigel Announces Presentation at the Upcoming IDWeek 2023
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical...
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...
Commit To Buy Rigel Pharmaceuticals At $1, Earn 41.5% Annualized Using Options
Rigel to Present at the 2023 Cantor Global Healthcare Conference
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company...
Rigel to Participate in Upcoming September Investor Conferences
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean...
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2023, including sales of...
3 Stocks to Buy for Lottery Jackpot Style Returns
Although you can try your hand at the lottery, your odds of success are probably far better with stocks with high returns.
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....
Commit To Buy Rigel Pharmaceuticals At $1, Earn 17.3% Annualized Using Options
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®...
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and...
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the...
Rigel to Present at the Jefferies 2023 Global Healthcare Conference
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will...
3 Penny Stocks to Make You the Millionaire Next Door
Explore the world of high-risk, high-reward top penny stocks to buy and uncover promising investment opportunities.